Holen Sie sich die Stockscreener-App
95.76
0.90%
0.85
Handel nachbörslich:
95.76
Schlusskurs vom Vortag:
$94.91
Offen:
$94.88
24-Stunden-Volumen:
709.39K
Relative Volume:
0.67
Marktkapitalisierung:
$5.21B
Einnahmen:
$2.04M
Nettoeinkommen (Verlust:
$-162.34M
KGV:
-23.28
EPS:
-4.1129
Netto-Cashflow:
$-129.27M
1W Leistung:
+9.47%
1M Leistung:
+22.99%
6M Leistung:
+164.53%
1J Leistung:
+398.49%
1-Tages-Spanne:
$93.16
$96.00
1-Wochen-Bereich:
$87.08
$96.05
52-Wochen-Spanne:
$16.64
$96.05
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
95.76 | 5.17B | 2.04M | -162.34M | -129.27M | -4.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - AOL.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics EVP Sells $10M in Shares - National Today
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares - MarketBeat
Ryan Savitz, Dianthus Therapeutics CFO, sells $738k in DNTH stock - Investing.com Canada
Dianthus Therapeutics Insider Sold Shares Worth $738,844, According to a Recent SEC Filing - marketscreener.com
Dianthus (NASDAQ: DNTH) CFO exercises options, sells 8,224 shares under 10b5-1 plan - Stock Titan
Dianthus Therapeutics Upgraded to Strong Buy at Wolfe Research - National Today
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 90.2 USD By Investing.com - Investing.com Australia
Ryan Savitz files Form 144 to sell 8,224 shares (NASDAQ: DNTH) - Stock Titan
Dianthus Therapeutics (DNTH) details 2026 director, pay and auditor votes - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 90.2 USD - Investing.com
Wolfe Research Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month HighTime to Buy? - MarketBeat
Can Dianthus Therapeutics Inc expand into new marketsEarnings Growth Report & Low Risk High Reward Ideas - baoquankhu1.vn
Dianthus Therapeutics, Inc.Common Stock (DNTH) Stock Price, News, Quote & History - FinancialContent
Dianthus Therapeutics Announces Inducement Grants - National Today
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - The Motley Fool
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus gives 8 new employees stock options at $84.56 a share - Stock Titan
Aug Momentum: Can Dianthus Therapeutics Inc expand into new markets2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Dianthus Therapeutics, Inc. (DNTH) stock price, news, quote and history - Yahoo Finance UK
A Look At Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains - Sahm
Wedbush keeps outperform on Dianthus Therapeutics, Inc. (DNTH), highlights potential of Claseprubart in CIDP - MSN
Dianthus Therapeutics EVP Sells Over $9 Million in Shares - National Today
How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,492,461.00 in Stock - MarketBeat
Dianthus Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Wells Fargo Remains a Buy on Dianthus Therapeutics (DNTH) - The Globe and Mail
Dianthus Therapeutics(DNTH.US) Officer Sells US$9.49 Million in Common Stock - Moomoo
Dianthus Therapeutics stock hits 52-week high at 88.35 USD By Investing.com - Investing.com Australia
Dianthus therapeutics director Soteropoulos sells $47985 in stock By Investing.com - Investing.com Australia
Dianthus therapeutics director Soteropoulos sells $47985 in stock - Investing.com
Savitz of Dianthus sold $9.5m in DNTH stock - Investing.com UK
Savitz of Dianthus sold $9.5m in DNTH stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics Insider Sold Shares Worth $9,492,596, According to a Recent SEC Filing - marketscreener.com
Dianthus Therapeutics (DNTH) CFO exercises options, sells 114,367 shares - Stock Titan
Dianthus Therapeutics (DNTH) director exercises options then sells 599 shares - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 88.35 USD - Investing.com
Dianthus rises as FDA agrees with proposed changes to lead program - MSN
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):